By Chih-Wei Ten and Daniel Fu-Chang Tsai

He was young and healthy only days earlier. Then fulminant myocarditis led to cardiac arrest, prolonged resuscitation, and mechanical ventilation in the ICU. Circulation returned, but the neurological signs were grim. Seizures persisted. Brainstem reflexes weakened. Days passed with no meaningful neurological recovery. The family faced a question every ICU team recognises: had we waited long enough, or were we only prolonging dying? His father wanted treatment to continue for as long as possible. His mother feared that her son would not want further suffering with no realistic hope of recovery. His wife could not decide. Every conversation ended in tears, uncertainty, and silence.

This is where time-limited trials matter. A time-limited trial is not simply “try and see.” It is a structured agreement to continue specific treatment for a defined period, using agreed clinical indicators to judge whether meaningful improvement has occurred. At the reassessment point, the team and family return to the question together: is treatment still serving this patient’s goals? In our Journal of Medical Ethics paper, we argue that the value of time-limited trials is not merely clinical. It is ethical. A time-limited trial gives uncertainty a structure. It creates time for treatment, but also time for conversation, interpretation, grief, and moral reflection.

One week later, the reassessment point arrived. There was still no meaningful neurological recovery. The parents gradually came to accept a transition toward comfort-focused care. His wife struggled: “He always talked about our future. How can stopping treatment respect what he would have wanted?”

This disagreement did not mean that the time-limited trial had failed. It showed why such trials require ethical analysis. A time-limited trial does not automatically create consensus or clarify values. Families may disagree. Preferences may be unclear or may change. Cultural expectations may make withdrawal difficult to discuss. Clinicians may differ about when treatment has become non-beneficial. The ethical significance of a time-limited trial lies not in forcing agreement, but in creating a process through which disagreement can be named, examined, and addressed.

In this case, the ICU team and family continued to meet. Attention shifted not only to decisions, but also to grief support and preparation for loss. The family shared stories, expressed emotions, and accompanied him through his final days. What had begun as a desperate struggle against death became, imperfectly but meaningfully, a way to honour a life. This may be one of the most important contributions of time-limited trials. They resist two failures of modern intensive care: doing too much for too long, and giving up too soon. At their best, time-limited trials do not merely buy time. They make time morally accountable.

They tell families: we will try, but we will also reassess.

They tell clinicians: we may treat, but not without purpose.

And they tell patients, even when they cannot speak: your life matters, but so do your values, dignity, and the manner of your dying.

Note: The case presented above is a composite vignette informed by several clinical experiences. Patient and family details have been  modified to preserve confidentiality

Article: Ethical analysis on time-limited trials in critical care

Authors: Chih-Wei Ten¹ and Daniel Fu-Chang Tsai²

Affiliations:

1. Mackay Memorial Hospital, Taipei, Taiwan
2. Department and Graduate Institute of Medical Education and Bioethics, National Taiwan University College of Medicine, Taipei, Taiwan

Competing interests: The authors reported no potential conflict of interest.